🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
To evaluate whether PF-02545920 reduces the effects of ketamine on brain ac...
Status
Terminated
Location
Pfizer Investigational Site
Start Date
2011-04
Trial ID
NCT01244880
Treatments Being Tested
To assess if PF-04958242 can attenuate the ketamine-induced cognitive impai...
Status
Completed
Location
Pfizer Investigational Site
Start Date
2012-12
Trial ID
NCT01749098
Treatments Being Tested
The purpose of this study is to assess the relative feasibility of 2 potent...
Status
Completed
Location
University of California Davis
Start Date
2014-05
Trial ID
NCT02134951
Treatments Being Tested
This phase Ib study aims to evaluate applicability of touchscreen-based cog...
Status
Unknown
Location
University of Eastern Finland, Clinical Research Centre, Brain Research Unit
Start Date
2018-03-12
Trial ID
NCT03469089
Treatments Being Tested
This study investigates the common features of electrophysiological measure...
Status
Completed
Location
VHA CT
Start Date
2007-12
Trial ID
NCT02675530
Treatments Being Tested
The proposed study is the first to explore the contribution of brain glutam...
Status
Completed
Location
VA Connecticut Healthcare System
Start Date
2001-03
Trial ID
NCT00588952
Treatments Being Tested
Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.T...
Status
Completed
Location
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
Start Date
2008-01-22
Trial ID
NCT00700076
Treatments Being Tested
The purpose of the study is 1. To establish the feasibility of fMRI studie...
Status
Completed
Location
Connecticut Mental Health Center
Start Date
2008-08
Trial ID
NCT01600885
Treatments Being Tested